Jeffrey R Sachs

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 9

Top Topics

Respiratory Syncytial Virus

Electronic Health Record

Liquid Chromatography Tandem Mass Spectrometry

Top Venues

BMC medical research methodology

CPT: pharmacometrics & systems pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Julie Dudášová, Zdeněk Valenta, Jeffrey R Sachs
Elucidating vaccine efficacy using a correlate of protection, demographics, and logistic regression. BMC medical research methodology 24 (1) (2024)
Julie Dudášová, Zdeněk Valenta, Jeffrey R Sachs
Elucidating vaccine efficacy using a correlate of protection, demographics, and logistic regression. BMC medical research methodology 24 (1) (2024)
Daniel I S Rosenbloom, Julie Dudášová, Casey Davis, Radha A Railkar, Nitin Mehrotra, Jeffrey R Sachs
Replicate Testing of Clinical Endpoints Can Prevent No-Go Decisions for Beneficial Vaccines. Vaccines 11 (9) (2023)
Josiah Ryman, Jessica Weaver, Tianyan Hu, Daniel M Weinberger, Ka Lai Yee, Jeffrey R Sachs
Predicting vaccine effectiveness against invasive pneumococcal disease in children using immunogenicity data. NPJ vaccines 7 (1) (2022)
Josiah Ryman, Jessica Weaver, Ka Lai Yee, Jeffrey R Sachs
Predicting effectiveness of the V114 vaccine against invasive pneumococcal disease in children. Expert review of vaccines 21 (10) (2022)
Jos Lommerse, Nele Plock, S Y Amy Cheung, Jeffrey R Sachs
V2 ACHER: Visualization of complex trial data in pharmacometric analyses with covariates. CPT: pharmacometrics & systems pharmacology 10 (9) (2021)
Sean M S Hayes, Jeffrey R Sachs, Carolyn R Cho
From complex data to biological insight: 'DEKER' feature selection and network inference. Journal of pharmacokinetics and pharmacodynamics (2021)
Julie Dudášová, Regina Laube, Chandni Valiathan, Matthew C Wiener, Ferdous Gheyas, Pavel Fišer, Justina Ivanauskaite, Guanghan Frank Liu, Jeffrey R Sachs
A method to estimate probability of disease and vaccine efficacy from clinical trial immunogenicity data. NPJ vaccines 6 (1) (2021)
Antonios O Aliprantis, Christine A Shaw, Paul Griffin, Nicholas Farinola, Radha A Railkar, Xin Cao, Wen Liu, Jeffrey R Sachs, Christine J Swenson, Heather Lee, Kara S Cox, Daniel S Spellman, Colleen J Winstead, Igor Smolenov, Eseng Lai, Tal Zaks, Amy S Espeseth, Lori Panther
A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults. Human vaccines & immunotherapeutics 17 (5) (2020)